(i) The information set forth under Items 1.01, 7.01 and 9.01 of the Current Report on Form 8-K filed by Aimmune Therapeutics, Inc. (the Company or Aimmune) on August 31, 2020 (including all exhibits attached thereto and incorporated therein by reference) is
incorporated herein by reference.
(ii) On August 31, 2020, Dr. Jayson Dallas, the Companys President and Chief Executive Officer,
provided the electronic communication attached hereto as Exhibit 99.1 to the Companys employees.
(iii) On August 31, 2020, the Company
presented the slides attached hereto as Exhibit 99.2 to its employees at a town hall meeting.
(iv) On August 31, 2020, the Company provided the
questions and answers attached hereto as Exhibit 99.3 to its employees.
(v) On August 31, 2020, the Company published the following posts to its
social media accounts:
Twitter:
Weve entered
into a definitive agreement with an entity part of @NestleNHSc to acquire #Aimmune for $34.50 per share. Together, were excited by the prospect of transforming the lives of millions of people with food allergies.
Read more: https://bwnews.pr/3gG76F5
LinkedIn:
Weve entered into a definitive agreement with an entity part of Nestlé Health Science to acquire Aimmune Therapeutics for $34.50 per share. We are
proud to be recognized for the value that the #Aimmune team has created and are excited by the prospect of transforming the lives of millions of people with food allergies.
Nestlé Health Sciences leadership in consumer health, extensive capabilities, global reach, and their alignment with our vision of pioneering
treatments and solutions for food allergies is a strong fit for our company. With Nestlé Health Sciences resources, our portfolio will be developed more broadly and rapidly, and will eventually reach more patients than Aimmune could
have on our own. They share our vision for transforming the lives of millions of people living with food allergies.
Read more: https://bwnews.pr/3gG76F5
Facebook:
Weve entered into a definitive
agreement with an entity part of Nestlé Health Science to acquire Aimmune Therapeutics. Nestlé Health Sciences leadership in consumer health, nutritional science, extensive capabilities, global reach, and their alignment with our
vision of pioneering treatments and solutions for food allergies is a strong fit for our company. With Nestlé Health Sciences resources, our portfolio will be developed more broadly and rapidly, and will eventually reach more patients
than Aimmune could have on our own. They share our vision for transforming the lives of millions of people living with food allergies.
Read more:
https://bwnews.pr/3gG76F5
***